https://www.selleckchem.com/products/tng260.html
For rare cancers, challenges in establishing standard therapies are greater than those for major cancers and effective methods are needed. MASTER KEY project is a multicenter study based in Japan, with two main parts prospective registry study and multiple clinical trials. Advanced rare cancers, cancers of unknown primary origin, and those with rare tissue subtypes of common cancers are targeted. The registry study accumulates highly reliable consecutive data that can be used for future drug development. The multiple trials are conducted
Like
Comment
Share
